Anti-Inflammatory Activity of Sodium Narcistatin (Pettit)

Yung Chang (Inventor)

Research output: Patent


THERAPEUTIC APPLICATIONS Rheumatoid arthritis Possibly other autoimmune diseases, such as, IBD, Crohns Disease, Ulcerative Colitis, Atherosclerosis, etc. EFFICACY In the adjuvant induced arthritis model in rats, SNS, dosed orally, reduces dorsoplantar swelling in a dose dependent manner. More significantly, SNS also displays dose dependent bone sparing activity. Dose dependent reductions in: Joint space narrowing Bone erosion Osteoporosis Periosteal bone formation.SNS outperforms both methotrexate and Remicade in this model.SAFETY SNS displays a benign safety profile in preliminary tox studies. No effects on general health, body weight, serum chemistries. Gross organ exam normal.MECHANISM OF ACTION SNS works early in the inflammatory cascade, hence inhibiting the action of many downstream cytokines.OTHER FEATURES SNS (& analogs) has solid IP protection. SNS synthesis is straightforward and inexpensive. SNS is highly water soluble. There is scope for more SAR on SNS.Download original PDF
Original languageEnglish (US)
StatePublished - Dec 1 2003


Dive into the research topics of 'Anti-Inflammatory Activity of Sodium Narcistatin (Pettit)'. Together they form a unique fingerprint.

Cite this